|Bid||15.73 x 900|
|Ask||25.00 x 1000|
|Day's Range||15.70 - 16.14|
|52 Week Range||10.19 - 20.95|
|Beta (5Y Monthly)||0.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 01, 2020 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company”, “we”, or “our”), a clinical-stage oncology company developing.
Four abstracts regarding zenocutuzumab (“Zeno”), including results from an independent epidemiology study of the prevalence of NRG1 gene fusion-positive (“NRG1+”) cancers, will be presented at the American Society for Clinical Oncology ASCO20 Virtual Scientific Program (ASCO), May 29-31, 2020. Abstracts detailing interim data from the Phase 1 MCLA-117 acute myeloid leukemia (AML) trial and an analysis of an extensive, proprietary panel of CD3 bispecific antibodies will be presented at the 25th European Hematology Association (EHA) Annual Congress Virtual Edition, June 11-14, 2020.
MCLA-128, zenocutuzumab, Phase 1/2 eNRGy trial remains on track MCLA-117 program update to be presented at upcoming medical meeting Anand Mehra, M.D. to succeed Russell Greig,.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 12, 2020 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, or “our”), a clinical-stage oncology company developing innovative,.
VICTORIA and UTRECHT, The Netherlands , Jan. 9, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced that its wholly owned subsidiary U-Protein Express BV signed a long-term lease contract for the new multi-tenant building for life sciences "Accelerator" at the Utrecht Science Park ( Utrecht, The Netherlands ). In addition to accommodating large biotechnology companies, the new building will offer space to companies that want to accelerate their development.
— Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer —— Ton Logtenberg, Ph.D., to step down after 16 years of leadership —— Transition to occur December.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 12, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage company developing.
Merus N.V. (MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the pricing of an underwritten public offering of 4,750,000 common shares, at a public offering price of $14.50 per share, before underwriting discounts and commissions. Merus also granted the underwriters a 30-day option to purchase up to an additional 712,500 common shares. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $68.9 million, excluding any exercise of the underwriters’ option to purchase additional common shares.
Merus N.V. (MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announced the launch of a proposed underwritten public offering of up to $60.0 million of its common shares. All of the common shares are being offered by Merus N.V. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional $9.0 million of its common shares at the public offering price, on the same terms and conditions. The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Merus N.V. (MRUS), a clinical-stage company developing innovative, full-length bispecific antibodies (Biclonics®), today announced initial clinical data for three patients with cancers harboring NRG1 fusions treated with MCLA-128 through an Early Access Program (EAP), and provided an overall update on the MCLA-128 clinical programs. Data on the three EAP patients were presented today by study investigators at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. Investigators from Memorial Sloan Kettering Cancer Center (MSKCC) provided a summary and initial data concerning the treatment of three cancer patients harboring NRG1 fusions with MCLA-128 at 750 mg administered intravenously every other week. These patients’ NRG1 gene fusions were identified using RNA-based sequencing.
UTRECHT, The Netherlands and BOSTON, Oct. 25, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage bispecific antibody company developing.
UTRECHT, The Netherlands, Aug. 19, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,.